GlaxoSmithKline’s Benlysta has been on the market for almost a decade, but it still has some tricks up its sleeve – it’s just become the first and only FDA-approved treatment for lupus ...
It is notoriously hard to treat effectively. Saphnelo will compete in the market most closely with GlaxoSmithKline's BLyS inhibitor Benlysta (belimumab), which has been available in the EU to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback